NDA 202293 · Astrazeneca Ab
Farxiga
Dapagliflozin · Oral
NovelBreakthrough therapyLast checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jan 8, 2014
Approved uses
9
Original approval plus efficacy supplements
Registered trials
659
182 Phase 3, 102 recruiting
FAERS reports
60,513
46,653 serious, 10,454 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 18, 2026.
FARXIGA (dapagliflozin) is indicated: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . FARXIGA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. (1) To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. (1) To reduce the risk of hospitalization for...
Mechanism: Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of...
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2024 Supplement 31 · Efficacy · priority review LetterLabelMedication Guide
- May 8, 2023 Supplement 26 · Efficacy LabelLetterReview
- Apr 30, 2021 Supplement 24 · Efficacy · priority review Breakthrough therapyLabelLetterReview
- May 5, 2020 Supplement 20 · Efficacy · priority review LabelLetterReview
- Oct 18, 2019 Supplement 18 · Efficacy LabelLetterReview
- Feb 22, 2019 Supplement 15 · Efficacy LabelLetter
- Oct 20, 2017 Supplement 12 · Efficacy LetterLabel
- Mar 11, 2015 Supplement 2 · Efficacy LetterLabel
- Jan 8, 2014 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
2 products under this application
- FARXIGA · DAPAGLIFLOZIN 10MG · TABLET, ORAL · Prescription · TE AB
- FARXIGA · DAPAGLIFLOZIN 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dapagliflozin" as an intervention, any sponsor and status, largest first.
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordPivotal-lookingRecruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT06642272 · 17,200 participants (planned) · Start Oct 10, 2024 · Primary completion Dec 31, 2028
Drug: Empagliflozin 10 MG; Dapagliflozin 10 MG · For: Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 12 sites in all
- Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01730534 · 17,190 participants · Start Apr 25, 2013 · Primary completion Sep 11, 2018
Drug: Dapagliflozin 10 mg; Placebo tablet · For: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Sites: Alexander City, Alabama; Athens, Alabama; Birmingham, Alabama · 805 sites in all
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06677060 · 11,300 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 17, 2029
Drug: Baxdrostat and dapagliflozin · For: Heart Failure
Sites: Birmingham, Alabama; Centreville, Alabama; Fairhope, Alabama · 977 sites in all
- Polypills Approach for Multiple Cardiovascular Risk FactorsPivotal-lookingRecruiting
China Medical University, ChinaAcademic, hospital or other
NCT07679828 · 8,252 participants (planned) · Start Jul 11, 2026 · Primary completion Dec 31, 2029
Drug: Fixed-Dose Combination Strategy · For: Hypertension; Dyslipidemia; Diabetes
Sites: Zhengzhou, China; Chifeng, China; Tongliao, China · 15 sites in all
- Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03619213 · 6,263 participants · Start Aug 27, 2018 · Primary completion Mar 27, 2022
Drug: Dapagliflozin; Placebo · For: Heart Failure With Preserved Ejection Fraction
Sites: Fairhope, Alabama; Mobile, Alabama; Sheffield, Alabama · 348 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
- Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart FailurePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03036124 · 4,744 participants · Start Feb 8, 2017 · Primary completion Jul 17, 2019
Drug: Dapagliflozin; Placebo · For: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Sites: Fairhope, Alabama; Mobile, Alabama; Sheffield, Alabama · 419 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death8,511
- fatigue2,672
- nausea2,619
- diarrhoea2,478
- dizziness2,464
- dyspnoea2,308
- off label use2,128
- weight decreased2,048
- acute kidney injury2,047
- blood glucose increased2,010
- vomiting1,936
- headache1,789
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 10 |
| 2010 | 9 |
| 2011 | 7 |
| 2012 | 11 |
| 2013 | 9 |
| 2014 | 860 |
| 2015 | 1,530 |
| 2016 | 1,255 |
| 2017 | 1,288 |
| 2018 | 1,574 |
| 2019 | 1,468 |
| 2020 | 1,724 |
| 2021 | 2,889 |
| 2022 | 5,131 |
| 2023 | 8,710 |
| 2024 | 11,383 |
| 2025 | 12,936 |
| 2026 | 9,718 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Farxiga (Dapagliflozin Propanediol)
2024 spending
$5.29B
Beneficiaries
1,269,216
5,634,650 claims
Per beneficiary
$4,168
$18.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $736,787,564 |
| 2021 | $1,421,505,274 |
| 2022 | $2,584,621,150 |
| 2023 | $4,342,182,307 |
| 2024 | $5,290,548,963 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV, Solomon SD, Inzucchi SE, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
Berg DD, Patel SM, Haller PM, et al. · Circulation 2025 · Meta-Analysis, Randomized Controlled Trial
- Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD, Raz I, Bonaca MP, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Claggett B, et al. · N Engl J Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.
Lin J, Huang Y, Xu B, et al. · BMJ 2025 · Randomized Controlled Trial, Multicenter Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.